DESIGN AND PARTICIPANTS: A double-blind, crossover, randomized study was designed to evaluate the effect of 3-month treatment with a lower versus a higher antihypertensive dosage of ramipril (5 or 10 mg/day) on nitric oxide (NO)-dependent vasodilation in 46 untreated patients with essential hypertension. Radial artery flow-mediated dilation (FMD), before and after the intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA), to block NO synthase, and the response to sublingual glyceril trinitrate (GTN, 25 microg) were measured at baseline and after the two treatment periods as a change in artery diameter (computerized system from ultrasound scans). Plasma angiotensin II and oxidative stress markers were also assessed. RESULTS:FMD was significantly (P < 0.01) lower in hypertensive patients (4.6 +/- 1.8%) than in normotensive subjects (7.1 +/- 2.6%), whereas the response to GTN was similar. L-NMMA significantly (P < 0.001) inhibited FMD in normotensive but not in hypertensive subjects. Mean 24-hambulatory blood pressure, plasma angiotensin II and oxidative stress marker levels were similarly reduced at the end of the two treatment periods. Both dosages of ramipril significantly (P < 0.001) increased FMD (5 mg: 5.9 +/- 2.1%; 10 mg: 6.3 +/- 2.4%) without modifying the response to GTN. However, compared with baseline (11 +/- 19%), the inhibiting effect of L-NMMA on FMD (NO-dependent FMD) was significantly (P < 0.01) greater with ramipril 10 mg (49 +/- 12%) than 5 mg per day (38 +/- 15%). The improvement in FMD and NO-dependent FMD was not related to changes in plasma levels of angiotensin II or markers of oxidative stress. CONCLUSION: Treatment with ramipril at a higher dosage induced a greater improvement in NO-dependent vasodilation compared with the lower antihypertensive dosage in hypertensive patients.
RCT Entities:
DESIGN AND PARTICIPANTS: A double-blind, crossover, randomized study was designed to evaluate the effect of 3-month treatment with a lower versus a higher antihypertensive dosage of ramipril (5 or 10 mg/day) on nitric oxide (NO)-dependent vasodilation in 46 untreated patients with essential hypertension. Radial artery flow-mediated dilation (FMD), before and after the intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA), to block NO synthase, and the response to sublingual glyceril trinitrate (GTN, 25 microg) were measured at baseline and after the two treatment periods as a change in artery diameter (computerized system from ultrasound scans). Plasma angiotensin II and oxidative stress markers were also assessed. RESULTS:FMD was significantly (P < 0.01) lower in hypertensivepatients (4.6 +/- 1.8%) than in normotensive subjects (7.1 +/- 2.6%), whereas the response to GTN was similar. L-NMMA significantly (P < 0.001) inhibited FMD in normotensive but not in hypertensive subjects. Mean 24-h ambulatory blood pressure, plasma angiotensin II and oxidative stress marker levels were similarly reduced at the end of the two treatment periods. Both dosages of ramipril significantly (P < 0.001) increased FMD (5 mg: 5.9 +/- 2.1%; 10 mg: 6.3 +/- 2.4%) without modifying the response to GTN. However, compared with baseline (11 +/- 19%), the inhibiting effect of L-NMMA on FMD (NO-dependent FMD) was significantly (P < 0.01) greater with ramipril 10 mg (49 +/- 12%) than 5 mg per day (38 +/- 15%). The improvement in FMD and NO-dependent FMD was not related to changes in plasma levels of angiotensin II or markers of oxidative stress. CONCLUSION: Treatment with ramipril at a higher dosage induced a greater improvement in NO-dependent vasodilation compared with the lower antihypertensive dosage in hypertensivepatients.
Authors: Beth A Parker; Michael E Tschakovsky; Amanda L Augeri; Donna M Polk; Paul D Thompson; Francis J Kiernan Journal: Am J Physiol Heart Circ Physiol Date: 2011-06-03 Impact factor: 4.733
Authors: Matthew A Ziegler; Matthew R Distasi; Randall G Bills; Steven J Miller; Mouhamad Alloosh; Michael P Murphy; A George Akingba; Michael Sturek; Michael C Dalsing; Joseph L Unthank Journal: Microcirculation Date: 2010-01 Impact factor: 2.628
Authors: Hossam A Shaltout; Joel Eggebeen; Anthony P Marsh; Peter H Brubaker; Paul J Laurienti; Jonathan H Burdette; Swati Basu; Ashley Morgan; Patricia C Dos Santos; James L Norris; Timothy M Morgan; Gary D Miller; W Jack Rejeski; Amret T Hawfield; Debra I Diz; J Thomas Becton; Daniel B Kim-Shapiro; Dalane W Kitzman Journal: Nitric Oxide Date: 2017-05-23 Impact factor: 4.427
Authors: D Walter Wray; Melissa A H Witman; Stephen J Ives; John McDaniel; Joel D Trinity; Jamie D Conklin; Mark A Supiano; Russell S Richardson Journal: Hypertension Date: 2013-06-17 Impact factor: 10.190
Authors: Scott T McEwen; Sarah F Balus; Matthew J Durand; Julian H Lombard Journal: Am J Physiol Heart Circ Physiol Date: 2009-08-14 Impact factor: 4.733
Authors: C E Storniolo; R Casillas; M Bulló; O Castañer; E Ros; G T Sáez; E Toledo; R Estruch; V Ruiz-Gutiérrez; M Fitó; M A Martínez-González; J Salas-Salvadó; M T Mitjavila; J J Moreno Journal: Eur J Nutr Date: 2015-10-08 Impact factor: 5.614